Umfula Biotech is a cutting-edge brand that specializes in the development of effective compounds for various wound healing objectives. With a strong focus on skin cell regeneration, Umfula Biotech aims to address the growing wound healing market, which is projected to exceed $24 billion by 2024. The brand's clinical objectives include surgical, trauma, chronic ulcers, and burns.

In addition to wound healing, Umfula Biotech also ventures into the field of bone regeneration. With the US bone regeneration market expected to be worth $6 billion by 2026, Umfula Biotech utilizes its expertise to develop effective plant-based solutions for trauma and osteoporosis.

Furthermore, Umfula Biotech is actively involved in the anti-inflammatory market. With a massive market value of over $100 billion in 2020, Umfula Biotech aims to discover novel compounds in several plants accessible in South Africa to combat trauma and chronic inflammation.

Umfula Biotech is led by a team of highly qualified professionals, including Dr. Alan Gould, who holds a PhD in Human Anatomy and has extensive experience in wound healing research. The brand also benefits from the expertise of Phanuel Majozi and Daniel Miles, who bring traditional healing knowledge and technological insight, respectively. Additionally, Prof. Geoffrey Candy, a renowned biochemist, contributes his expertise in metabolism, wound healing, and cancers.

Umfula Biotech ensures that all its work is carried out ethically and legally, in compliance with the South African NEMBA 2004 regulations. For any inquiries or collaboration opportunities, Umfula Biotech can be reached through their LinkedIn page or via email at [email protected].